Read + Share
Hitzler J, Alonzo T, Gerbing R, Beckman A, et al. High-dose AraC is essential for the treatment of ML-DS independent of
postinduction MRD: results of the COG AAML1531 trial. Blood 2021;138:2337-2346.
PMID: 34320162
|
 |
|
Hitzler J, Alonzo T, Gerbing R, Beckman A, et al. High-dose AraC is essential for the treatment of ML-DS independent of
postinduction MRD: results of the COG AAML1531 trial. Blood 2021;138:2337-2346.
PMID: 34320162
|
|
|
|